Skip to main content
REVB logo

REVB · Revelation Biosciences, Inc. · Documents

Track REVB — free
$3.71 +0.02 (+0.54%)
Market Cap
$2.52M
Shares
683,442
Volume · Nov 20 1858 Avg daily vol (23 sessions) 20.32K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $8.91M 10-K filed Feb 26, 2026 Quarterly report FY2026 Q3 Net loss $3.32M 10-Q filed Nov 5, 2026 Latest results Funding through second quarter of 2027 depends on operating plans 8-K filed Nov 5, 2026
2026
Nov 13
Current report 8-K
Social media designated for potential material disclosures

Revelation Biosciences, Inc. said it may use social media channels to communicate material information and comply with Regulation FD, while clarifying that such disclosures are neither furnished nor filed under the Securities Exchange Act of 1934.

Regulation FD disclosure
2 source passages
Revelation Biosciences, Inc. (the “Company”) wishes to notify the investment community and others that in the future, we may choose to communicate material information about us and our services and for complying with our disclosure obligation under Regulation FD via social media channels. Neither the information in this Item 7.01 or any social media post are to be deemed to be “furnished” and shall not be deemed to be “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act. Open the document at this passage
Nov 5
Current report 8-K
Funding through second quarter of 2027 depends on operating plans

Revelation Biosciences, Inc. reported $9.1 million in cash as of September 30, 2026 and, based on current operating plans and projections, believes it can fund operations into the second quarter of 2027; nine-month net loss was $9.6 million.

Financial results
3 source passages
As of September 30, 2026, Revelation had $9.1 million in cash and cash equivalents, compared to $10.7 million as of December 31, 2025. Based on current operating plans and projections, Revelation believes its current cash and cash equivalents are sufficient to fund operations into the second quarter of 2027. Net loss for the nine months ended September 30, 2026 was $9.6 million, or $29.37 basic and diluted net loss per share compared to net loss of $6.4 million, or $273.33 basic and diluted net loss per share for the nine months ended September 30, 2025. Open the document at this passage
Nov 5
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Cash shortage and Nasdaq delisting risk

Revelation says cash is insufficient, raising substantial going-concern doubt, with $9.1 million available and a $59.1 million deficit as of September 30, 2026; Nasdaq delisting is possible if market value stays below $5 million for 30 consecutive business days.

Net loss $3.32M Diluted EPS -$5.92
Read from the MD&A section
5 source passages
We do not anticipate that our current cash and cash equivalents balance will be sufficient to sustain operations within one year after the date that our unaudited financial statements for September 30, 2026 were issued, which raises substantial doubt about our ability to continue as a going concern. As of September 30, 2026 we had an accumulated deficit of $59.1 million, a stockholders’ equity of $7.2 million and available cash and cash equivalents of $9.1 million. Revelation’s common stock and Public Warrants are listed on the Nasdaq Capital Market listing tier (“Nasdaq Capital Market”) under the symbols “REVB” and “REVBW,” respectively. The new MVLS Rule eliminates any cure period, precludes any automatic stay of suspension pending an appeal, and results in an immediate trading suspension upon Nasdaq’s determination of non-compliance. Given that the current market value of the Company’s listed securities is below $5 million, the MVLS Rule would result in the delisting of the Company’s securities from Nasdaq should the market value of its listed securities remain below $5 million for 30 consecutive business days. Open the document at this passage
Jun 1
Current report 8-K
Other events AI summary on its way
May 11
Proxy statement DEF 14A Meeting Jun 24, 2026
Proxy statement AI summary on its way
Apr 30
Proxy statement PRE 14A Meeting Jun 24, 2026
Proxy statement AI summary on its way
Feb 26
Annual report 10-K FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Net loss $8.91M Diluted EPS -$23.95
Jan 22
Current report 8-K Events of Jan 21
Other events AI summary on its way
2025
Showing 1–50 of 197 documents
Key facts CIK 1810560 CUSIP 76135L887 13F (30d) 16 filings 14 filers Visit website Investor relations